Syndax Pharmaceuticals Inc SNDX 深 沪
等待开盘 08-25 09:30:00 美东时间
19.73
+0.080
+0.41%
华盛通- 最 高19.87
- 今 开19.69
- 成交量 83.32万股
- 最 低 19.17
- 昨 收 19.65
- 总市值 17.62亿
- 52周最高 25.59
- 市盈率 静 --
- 换手率 0.93%
- 52周最低 12.99
- 委 比 13.64%
- 总股本 8929.71万
- 历史最高 29.86
- 量 比 0.78
- 振 幅 3.56%
- 历史最低 3.39
- 每 手 1
- 风险率 2.94%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 罗斯百货、迪尔股份获多家大行上调目标价；沃尔玛、Advance遭多家大行下调目标价
今日重点评级关注：摩根士丹利：维持Ultragenyx Pharmaceutical"超配"评级，目标价从67美元升至74美元；Truist Securities：维持Solid Biosciences"买入"评级，目标价从16美元升至20美元
08-24 16:40
UBS Maintains Buy on Syndax Pharmaceuticals, Lowers Price Target to $33
UBS analyst David Dai maintains Syndax Pharmaceuticals (NASDAQ:SNDX) with a Buy and lowers the price target from $37 to $33.
08-21 23:44
美股大行评级 | 潜在涨幅207.38%！Truist Securities上调AbCellera Biologics目标价至30美元，维持"买入"评级
今日重点评级关注：Truist Securities：维持AbCellera Biologics"买入"评级，目标价从12美元升至30美元；Stifel：维持Proficient Auto Logistics"买入"评级，目标价从9美元升至12美元
08-12 08:45
美股大行评级 | AMD、Arista Networks、Booking 、加特纳、Pinterest、科力斯、Wayfair等获多家大行上调目标价
今日重点评级关注：HC Wainwright & Co.：维持Precigen"买入"评级，目标价从14美元升至18美元；HC Wainwright & Co.：维持Sophia Genetics"买入"评级，目标价从12美元升至14美元
08-06 11:36
HC Wainwright & Co. Maintains Buy on Syndax Pharmaceuticals, Lowers Price Target to $38
HC Wainwright & Co. analyst Andres Y. Maldonado maintains Syndax Pharmaceuticals (NASDAQ:SNDX) with a Buy and lowers the price target from $40 to $38.
08-05 19:10
财报速睇 | Syndax Pharmaceuticals Inc 2026财年Q2营收0.73亿美元，同比增长91.8%；归母净利润亏损0.49亿美元，同比亏损缩窄31.3%
华盛资讯8月5日讯，Syndax Pharmaceuticals Inc公布2026财年Q2业绩，公司Q2营收0.73亿美元，同比增长91.8%，归母净利润亏损0.49亿美元，同比亏损缩窄31.3%。
08-05 09:10
财报速睇 | Syndax Pharmaceuticals Inc 2026财年Q2营收0.73亿美元，同比增长91.8%；归母净利润亏损0.49亿美元，同比亏损缩窄31.3%
华盛资讯8月5日讯，Syndax Pharmaceuticals Inc公布2026财年Q2业绩，公司Q2营收0.73亿美元，同比增长91.8%，归母净利润亏损0.49亿美元，同比亏损缩窄31.3%。
08-05 07:42
Syndax Pharmaceuticals Q2 EPS $(0.55) Misses $(0.49) Estimate, Sales $72.788M Miss $79.323M Estimate
Syndax Pharmaceuticals (NASDAQ:SNDX) reported quarterly losses of $(0.55) per share which missed the analyst consensus estimate of $(0.49) by 12.24 percent. This is a 33.73 percent increase over losses of $(0.83) per share from the same period last year. The company reported quarterly sales of $72.7...
08-05 04:03
Syndax to Announce Second Quarter 2026 Financial Results and Host Conference Call and Webcast on August 4, 2026
Syndax Pharmaceuticals will report its second quarter 2026 financial results and provide a business update on August 4, 2026. Management will host a conference call and live audio webcast at 4:30 p.m. ET on the same day. The webcast and slides can be accessed through the company's website. A replay will be available on the Investors section within 24 hours and remain accessible for 90 days. The company specializes in innovative cancer therapies, ...
07-28 11:00
美股大行评级 | 潜在涨幅284.62%！Annexon获Needham上调目标价至25美元；多家大行上调美国银行目标价
今日重点评级关注：Needham：维持Annexon"买入"评级，目标价从11美元升至25美元；Benchmark：维持Prenetics Global"买入"评级，目标价从30美元升至40美元
07-16 18:55
